Microbiotix, Inc.


Microbiotix, Inc. is a clinical stage biopharmaceutical company dedicated to the discovery and development of proprietary small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. The company is recognized for its innovation and has consistently been a top recipient of NIH awards among Massachusetts biotech/pharma companies.

Microbiotix

Microbiotix, Inc.


Patents

Metabolically stable N-acylaminooxadiazoles useful as antibacterial agents

2022-11-22 • US-11505533-B2

View Details

Broad spectrum inhibitors of filoviruses

2022-10-04 • US-11459308-B2

View Details

Inhibitors of bacterial type III secretion system

2016-05-17 • US-9340551-B2

View Details

Inhibitors of bacterial type III secretion system

2014-12-09 • US-8906945-B2

View Details

What We Do

A potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). MBX-400 has successfully completed Phase 1 clinical testing.



Key People

President & CEO

Chief Business Officer


News & Updates

Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.